Over the last 30 years, it has become increasingly clear the amount of bone (e.g., Bbone quantity^) and the quality of the bone matrix (e.g., Bbone quality^) both critically contribute to bone's tissue-level mechanical behavior and the subsequent ability of bone to resist fracture. Although determining the tissue-level mechanical behavior of bone through mechanical testing is relatively straightforward in the laboratory, the destructive nature of such testing is unfeasible in humans and in animal models requiring longitudinal observation. Therefore, surrogate measurements are necessary for quantifying tissue-level mechanical behavior for the pre-clinical and clinical evaluation of bone strength and fracture risk in vivo. A specific implementation of indentation known as reference point indentation (RPI) enables the mechanical testing of bone tissue without the need to excise and prepare the bone surface. However, this compromises the ability to carefully control the specimen geometry that is required to define the bone tissue material properties. Yet, the versatility of such measurements in clinical populations is provocative, and to date, there are a number of promising studies that have utilized this tool to discern bone pathologies and to monitor the effects of therapeutics on bone quality. Concurrently, ongoing efforts continue to investigate the aspects of bone material behavior measured by RPI and the compositional factors that contribute to these measurements. There are currently two variants, cyclic-and impact-RPI, that have been utilized in pre-clinical and clinical studies. This review surveys clinical studies that utilize RPI, with particular emphasis on the clinical instrument, as well as the endeavors to understand the fundamental mechanisms of such measurements. Ultimately, an improved awareness in the tradeoffs and limitations of in vivo RPI is critical towards the effective and successful utilization of this tool for the overall improvement of fragility determination in the clinic.
Introduction
The ability to resist fracture of whole bone is derived from the bone's geometry and tissue-level mechanical behavior [1, 2] . In turn, the tissue-level mechanical behavior, such as crackgrowth toughness, fracture toughness, material strength, and fatigue characteristics, are controlled by both bone mass and quality of the bone tissue [2] . Bone mass is defined here as the quantity of bone that can be clinically measured by dual x-ray absorptiometry (DXA) [3] , and bone quality is defined as the microstructural and compositional factors beyond those measurable by DXA [4, 5] including but not limited to collagen crosslinking [6] , trabecular architecture [7] , degree of mineralization [8] , hydration [9] , and noncollagenous proteins [10] .
Although the characterization of bone tissue mechanical behavior is relatively straightforward in the laboratory [11, 12] , mechanical testing requires the careful preparation of the test sample, and the testing process itself inevitably damages the sample. Although it also requires specimen preparation, indentation damages only the tissue surrounding the site of indentation, rather than the entire sample. Indentation measurements quantify the resistance of the material to plastic deformation, and this is commonly used to infer the bone's plasticity relating to microcracking [13] . Even though classical indentation approaches (i.e., hardness testing and depthsensing indentation) were done on ex vivo and prepared samples, the recent development of reference point indentation (RPI) provides the promise of measuring bone tissue mechanical behavior in humans. Two related RPI devices, BioDent and OsteoProbe (Active Life Scientific, Santa Barbara, CA), have been developed for research and clinical research use (Fig. 1) . The OsteoProbe in particular has seen accelerated adoption in clinical studies. However, significant questions remain as to how the two devices, especially OsteoProbe, relate to whole-bone fracture behavior and bone tissue material properties measured by traditional quasi-static mechanical testing. Here, we provide a technical overview of indentation methods in bone, review clinical and pre-clinical studies (cadaveric) utilizing reference point indentation analysis, and discuss the mechanisms of these measurements as they apply to clinical studies.
Traditional Indentation Methods
Microscopy-based microhardness testing for bonemeasures material resistance to plastic deformation under constant compressive load between 0.6 mN and 2 N [14] . In general, indentation hardness testing applies a force P onto a prepared surface using a probe of defined geometry. The probe creates an impression of contact area A c determined by microscopy, and the hardness is calculated H = P/A c . The common probe geometries for microhardness testing include squarepyramidal (the Vickers test) and rhombic-pyramidal (the Knoop test). Traditional microhardness testing offers the advantage of being relatively straightforward; the major control parameters are indenter (probe) geometry, load, and dwell (hold) time. Microhardness testing in bone is also well-characterized, though the appropriate force must be carefully chosen for the site of interest [15] . Yet microscopy-based microhardness testing is unable to characterize purely elastic parameters. Though indentation hardness is generally wellcorrelated with both elastic modulus and yield stress in bone [16] , there is no convenient analytical method to derive either value from a hardness value alone. Additionally, hardness testing is impractical clinically, as it is subject to extremely stringent boundary conditions. In order for the area to be accurately determined, the indenter must touch down perpendicularly to a carefully prepared specimen surface with very little tolerance for angle deviation. In bones, sample preparation is required to remove surface roughness at the indenterbone contact surface [17] . The proper preparation requires significant technical expertise and would not be sufficiently high-throughput for routine biopsies in a clinical pathology laboratory.
With the advancement of controller technology, depthsensing indentation was developed to avoid the need for direct optical microscopic measurements. By utilizing traditional indenter geometries in conjunction with depth-sensing, it is then possible to generate a load-displacement curve and derive the indentation modulus, energy dissipation, and anisotropy in addition to hardness [14, 18] . The development of high-accuracy controllers also allowed these measurements to be obtained at the nano-scale [19] , enabling the mapping of mechanical features down to the size of individual osteons [20] . When applied to biopsies from clinical populations, nanoindentation analyses have revealed important insights in fragility in disparate populations such as those who suffered from atypical femoral fractures [21] . However, depth-sensing methods still have many of the same limitations as traditional microhardness testing including the need for surface polishing embedding for relatively small samples.
In recent years, microhardness testing and depthsensing indentation have been used to characterize a wide range of bones ex vivo. Boivin and colleagues performed hardness testing on biopsied iliac crest and calcanei [16] , and found significantly decreased microhardness in osteoporotic patients. Ossicles obtained from patients with normal and inflamed middle ears revealed a relationship between mineralization and hardness [22] . Similarly in cancellous bone, the Vickers microhardness of trabeculae in proximal femoral epiphyses was found to decrease with increasing severity of hip osteoarthritis [15] . 
Reference Point Indentation
The introduction of reference point indentation (RPI) has increased the feasibility of in vivo and in situ indentation testing of bone [23] [24] [25] [26] . Traditional hardness and depth-sensing indentation generate results that depend on precise measurement of indentation area, and they are thus highly sensitive to variations in the contact angle between the probe and the sample. This is nearly impossible to assure in vivo. RPI simplifies indentation by measuring indentation distance-based parameters of bone mechanical behavior and avoiding indentation area estimation altogether. Consequently, it is less susceptible to variations in contact angle [23, 24] . Furthermore, the reference probe design allows the test probe to reach the testing surface without having to make incisions on the superficial soft tissues [23] [24] [25] 27] . As a compromise, however, RPI generally does not allow the measurement of traditionally defined mechanical property parameters, and it utilizes a plastic (PMMA-polymethylmethacrylate) standard to minimize variance of penetration depth due to tip geometry. Two RPI devices have been developed, both by the same manufacturer (Active Life Scientific): BioDent 1000 and OsteoProbe RUO ( Fig. 1 ; Table 1 ). The devices appear to be minimally invasive, and there are no documented adverse complications related to the RPI measurements of more than 2000 human subjects [28] . Emerging research and subsequent debate has gone into correlating RPI with compositional and whole-bone parameters.
BioDent is a cyclic microindentation device utilizing dual probe assembly consisting of an outer reference probe and an inner test probe. The outer reference probe penetrates the skin and soft tissues and rests on the bone surface while the test probe engages and conducts measures on the bone tissue surface. This process can be done either by hand or through a mount. The 90 o cono-spherical inner test probe (375-μm diameter, 2.5-μm tip radius) then engages until the user-defined load force is achieved (between 2 and 10 N), then retracts. This occurs cyclically up to 20 times, depending on the desired number of cycles. The waveform is such that loading, peak force dwell, and unloading are each 1/3 of the cycle [29] . The system displays the force-displacement curve on the screen as testing occurs and outputs a set of result parameters at the end of the test. These include 1 st ID (indentation distance of the first cycle), TID (the total distance indented), IDI (indentation distance increase between first and last cycle), creep ID (distance increase during 1st cycle constant peak force), US (unloading slope), and energy dissipated (area inside force-displacement curve) [30] (Fig. 2a) . In contrast, the OsteoProbe is an impact indentation device with no outer reference probe. The test probe (375-μm tip diameter, < 10-μm tip radius) is pressed onto the bone surface with handheld force. When an applied force of 10 N is achieved, a spring mechanism activates and applies an additional 30-N force over 2.5 ms (Fig. 2b) . After the completion of the single-cycle indentation, the system outputs a dimensionless parameter, bone mineral strength index (BMSi). BMSi is defined as 100 multiplied by the indentation distance of the test (μm), divided by an assumed PMMA indentation distance of 150 μm. After the completion of all testing on a specimen (typically 5-10 indents [31] ), the user indents a PMMA block for calibration and the final BMSi values are calculated. Since the BioDent is a cyclic microindentation device and OsteoProbe utilizes impact microindentation, the two devices are inherently different and may measure different behaviors of bone [32] . A higher IDI from the BioDent generally reflects poor resistance to indentation, while a higher BMSi from the OsteoProbe suggests higher resistance against indentation. The peak force of OsteoProbe can be up to 20 times greater than BioDent, and the load rate is up to 30,000 times greater. Additionally, there are differences in the way the two devices penetrate the encasing soft tissue (Fig. 3) . With the BioDent, three probe assembly types are available (BP1, 2, and 3) with differing reference probe geometries. The BP1 is meant for penetration and scrape removal of soft tissue, whereas the BP2 and BP3 are meant for ex vivo large and small bones respectively. In contrast, the OsteoProbe punctures soft tissues with the 10-N initial force with the testing probe before engaging the bone tissue with the additional 30 N. Both RPI devices create indentations that contain microcracks that emanate from the tip and contain a combination of elastic, plastic, and damage processes (Fig. 4) .
OsteoProbe Studies
In recent years, clinical studies have been conducted almost exclusively with the OsteoProbe rather than the BioDent. This is unsurprising given the OsteoProbe is more user-friendly and perhaps more suitable for clinical implementation. A recent paper studied a group of 20 inactive but otherwise healthy postmenopausal women, before and after a short-term jumping exercise intervention [33] . For 3 months, the women were asked to jump on the same leg according to a prescribed exercise regimen. At both time points, DXA of the hip, femoral neck, and lumbar spine were conducted for aBMD measurement. HR-pQCT was conducted on the tibiae for quantitative morphometry, and BMSi was measured by OsteoProbe. The study found after 3 months, there were no changes in aBMD or microarchitecture at any site, but a significant 7% increase in BMSi in the intervention leg. Interestingly, BMSi change was also negatively correlated with lumbar spine aBMD, suggesting that those with lower bone mineral density may be more responsive to short-term, high-impact exercise. Another study recruited postmenopausal women with a history of distal radius fracture, hip fracture, and no fracture [34] and found that BMSi was significantly lower in the distal radius fracture group, even after adjustment for age, body mass, and femoral neck BMD. Though the unadjusted BMSi difference was significant, it was small (74.4 ± 8.8 for fracture vs. 77.4 ± 8.8 for controls), suggesting small differences in BMSi may be important for this fracture site. Conversely, the study found no significant differences in BMSi between the hip fracture and control group, and notes no study has found such a difference. Older women also suffer from increased incidence of vertebral fractures, thus the use of OsteoProbe in predicting vertebral fracture risk has also become an area of interest. One recent work performed tibial OsteoProbe indentation on a cohort of older women (n = 472, ages 75-80) and found BMSi, and radial-and tibial-cortical porosity do not differ to those who had a history of prevalent vertebral fracture [35] . Yet another study showed BMSi is reduced in patients that suffered from fractures independently of the fracture site [36] . Another study found neither BMSi nor lumbar aBMD were significantly different between non-osteoporotic vertebral fracture and non-fracture groups [37] . In contrast, Sosa and colleagues found a significant difference in BMSi and lumbar aBMD between control and osteoporotic (lumbar Tscore < − 2.5) vertebral fracture groups [38] . The discordance in these findings merits cautious interpretation and underscores the complex etiology of these fractures and a single measurement may not discern the fracture and non-fracture populations. More work is needed to determine the fundamental mechanisms responsible for the differences in these studies, and whether OsteoProbe is appropriate for fracture prediction at distant skeletal sites.
Since some therapies such as anti-inflammatory glucocorticoids may increase bone fragility before any changes in BMD can be detected [39] , the ability to monitor the changes in bone tissue mechanical behavior could provide valuable feedback in the treatment administration. Indeed, one of the first studies to use OsteoProbe for drug monitoring studied patients receiving intervention for glucocorticoid-induced osteoporosis [39] . Patients received calcium and vitamin D, as well as either teriparatide (for severe osteoporosis), denosumab, risedronate, or no additional drug. Patients on teriparatide, denosumab, and risedronate had significantly increased BMSi by 20 weeks. Conversely, patients on only calcium and vitamin D had a BMSi that decreased significantly by 11.4% at 7 weeks were subsequently switched to bisphosphonate intervention. Although limited in its relatively small cohort size and uncontrolled patients' inflammatory diseases and initial lumbar and femoral neck aBMDs, this study was the first to demonstrate the feasibility of using the Osteoprobe to monitor the effects of drug therapies on bone tissue quality. In another study, BMSi is significantly lower in postmenopausal women who suffered a fracture while receiving oral bisphosphonate treatment, compared to those who did not suffer a fracture [40] . This difference remained significant even after adjustment for age, gender, treatment time, and lumbar spine BMD.
Finally, OsteoProbe has been utilized in cohorts with diseases where bone quality may be compromised. In particular, individuals with type 2 diabetes (T2D) mellitus has been shown to exhibit compromised BMSi despite normal or higher-thannormal BMD and favorable microarchitecture across multiple studies [41] [42] [43] . Though the mechanisms driving reduced BMSi in diabetics are unclear, the changes BMSi has been associated with the accumulation of advanced glycation end products (AGEs) in human bone [32] and may be the putative mechanism for the fragility observed in T2D. BMSi has also been reported in other clinical morbidities, including chronic kidney disease and transplantation [44] , acromegaly [45] , Paget's disease [46] , Camurati-Engelmann disease, type 1 Gaucher disease [47] , and obesity [48] , with BMSi observed to be lower in the respective pathological cohorts.
BioDent Studies
As BioDent was the first commercial RPI instrument, it was also first utilized in clinical studies. In the initial clinical study [29] , Diez-Perez and colleagues studied a group of 27 women who suffered fracture requiring hospitalization (25 hip fractures, 2 multi-vertebral fractures), as well as 8 sex-matched controls. After adjustment for age, IDI was significantly greater in the fracture group than controls. A second clinical study [49] probed possible relationships between long-term bisphosphonate treatment and atypical femoral fracture. Four groups of patients were studied: controls with no fracture history, long-term bisphosphonate patients with no fracture, controls with a history of typical fracture, and long-term bisphosphonate patients with fracture. The study found TID and IDI were different between fracture and non-fracture groups, but did not detect differences due to bisphosphonates use alone.
A number of cadaver studies have been performed with BioDent RPI. One study found that IDI was correlated with femoral neck strength IDI (r = − 0.478), and utilizing aBMD and IDI together in a multivariate model significantly increased the predictive ability of bone strength (r = 0.883) than either measurement alone [50] . BioDent was also capable of monitoring the effects of in vitro aminoguanidine and pyridoxamine incubation on ex vivo bone tissue mechanical behavior [51] . In another application, IDI was used to predict maximum screw torque in fracture fixation [52] [53] [54] .
Studies Comparing OsteoProbe, BioDent, and Whole-Bone Mechanical Behavior To our knowledge, there have been no clinical studies that have directly compared both the BioDent and OsteoProbe measurements in humans at a population scale. However, cadaver studies provide the opportunity to compare the BioDent and Osteoprobe with other mechanical testing modalities [32, 55, 56] . Karim and co-authors suggest BioDent measures creep or fatigue crack growth from cyclic loading, whereas OsteoProbe is sensitive to energy dissipated from rapid loading [55] . Although Biodent and Osteoprobe measurements appear to be correlated in some cases, these measures appear to be differentially sensitive to various aspects of bone composition. For example, Uppuganti and colleagues [56] found cyclic RPI to be sensitive to tissue mineral density (r = − 0.89), and OsteoProbe to be sensitive to cortical porosity (r = − 0.90; Table 2 ). Abraham et al. [32] found that BMSi was more strongly correlated with advanced glycation end product (AGEs) content (r = − 0.613) than IDI (r = 0.281). In the same study, IDI and BMSi correlated with tissue mineral density roughly to the same degree (r = − 0.390; r = 0.430, respectively). Uppuganti et al. have also found correlations between quasi-static apparent level mechanical behavior in bending and BMSi [56] , while Abraham et al. [32] did not (Table 3 ). Yet whole-bone mechanical behavior appears to be correlated with IDI [50] , and Granke et al. [57] found moderate correlations between IDI and femoral cortical beambending parameters. Granke et al. [58] found only a weak correlation between IDI and crack initiation toughness at the tissue-level in prepared cortical beams.
Future Directions and Conclusion
In contrast to traditional indentation approaches, reference point indentation applies loads at a much higher rate, and this adds a degree of complexity in the material response of the bone tissue. As bone is a viscoelastic material [59] [60] [61] [62] , the quasi-static indentation approaches are designed to reduce the time-dependence of the intricately woven elastic-plastic processes and damage mechanisms invoked during testing [63] . The simplicity of use in RPI approaches concomitantly increases the phenomenological turbulence of the bone tissue in response to the mechanical loading. It thus perhaps is not surprising that studies that seek to reconcile RPI-derived measurements with quasi-static mechanical testing find varying degrees of correlation-and none in some cases. Tests such as tension and compression come with the luxurious simplicity of being able to compartmentalize the elastic and plastic response on a stress-strain curve, yet these processes are occurring simultaneously during indentation. To confound matters further, the high loading rate of the OsteoProbe invokes a substantial time-dependent hardening response that can only be effectively probed by dynamic mechanical analyses over loading frequencies spanning several orders of magnitude [62] . Finite element modeling studies help to elucidate the specific regional mechanisms and the constitutive behavior that occur in the dynamic reference point indentation measurements processes [64, 65] , but the development of these models require a clearer understanding of the hierarchical composition of material behavior at the relevant length scales.
Whether or not a significant change in BMSi between populations is meaningful remains an area of active investigation. Although tracking specific adverse clinical events prospectively (i.e., fracture, etc.) would be most informative of the predictive nature of BMSi, this is not always feasible. Additionally, there is a need to improve the understanding of the specific compositional factors that most strongly influence BioDent and OsteoProbe. Moreover, it appears that the two devices measure different aspects of bone mechanical behavior, so neither device will entirely capture all changes in bone tissue material quality. As a practical matter, understanding the relationship between composition and indentation-measured mechanical behavior will better identify the diseases populations that are mostly likely to benefit from these tools. A more fundamental understanding of RPI is also important if the technology is to gain wider adoption. Even as RPI's distance-based parameters applied in a dynamic manner may not fully recapitulate the parameters obtained from carefully controlled, laboratory-based quasi-static mechanical testing, RPI has enabled clinical measurements of bone tissue mechanical behavior where otherwise none could be done at all (save for biopsies). It is likely that the optimal clinical value of RPI will be achieved in combination with imaging, particularly when disparities between BMD and fracture risk are suspected. Clinically, these measures should be carefully interpreted in the context of the pathology and the patient, as multiple compositional factors can contribute to changes in measurements across populations. Moreover, it is to be cautioned that measurements such as those determined by RPI are intended to reflect only one aspect of bone health.
Funding The National Institutes of Health P30 AR057235, K01AR069116, and R21AR069804.
Compliance with Ethical Standards

